Accendra Health amends receivables securitization program

Item 1.01 Entry into a Material Definitive Agreement.

Amendment to Receivables Securitization Program

On October 29, 2026, Accendra Funding LLC ("Accendra Funding") and Byram Healthcare Centers, Inc. ("Byram") each a wholly-owned subsidiary of Accendra Health, Inc., entered into the Third Amendment to the Amended & Restated Receivables Purchase Agreement (the "RPA Amendment"), which amends that certain Amended & Restated Receivables Purchase Agreement, dated as of December 31, 2025, as amended, by and among Accendra Funding, as Seller, Byram, as Servicer, the persons from time to time party thereto, as Purchasers, PNC Bank, National Association ("PNC"), as Administrative Agent, and PNC Capital Markets LLC, as Structuring Agent (the "Receivables Purchase Agreement"). The RPA Amendment extends the Scheduled Termination Date until October 2029, with standard contingencies, and revises account control provisions and reporting obligations.

The foregoing description of the RPA Amendment is a summary, and is qualified in its entirety by reference to the complete terms of the RPA Amendment, a copy of which will be filed as an exhibit to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2026.

PNC Bank, National Association and PNC Capital Markets LLC have various relationships with the Company and its subsidiaries involving the provision of financial services, including investment banking, commercial banking, advisory, cash management, custody and trust services, for which they have received customary fees, and may do so again in the future.

Item 7.01 Regulation FD Disclosure.

On November 2, 2026, the Company issued a press release related to the foregoing. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in Exhibit 99.1 is being furnished pursuant to Item 7.01 of Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

The following materials are filed as exhibits to this Current Report on Form 8-K.

Exhibit Number

Description

99.1

Press Release of the Company, dated November 2, 2026 (furnished pursuant to Item 7.01).

104

Cover Page Interactive Data File ( the cover page XBRL tags are embedded in the Inline XBRL document ).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ACCENDRA HEALTH, INC.

November 2, 2026

/s/ Jonathan A. Leon

Jonathan A. Leon

Executive Vice President and Chief Financial Officer

Accendra Health Announces Extension of $150 Million Receivables Sale Program To 2029

Richmond, VA – November 2, 2026 – Accendra Health, Inc. (NYSE: ACH) (the "Company") today announced that it executed an amendment to its Receivables Purchase Agreement (the "Receivables Sale Program") on October 29, 2026. The amendment, among other things, extends the Scheduled Termination Date of the facility to October 2029, and the $150 million size of the Receivables Sale Program is unchanged.

"We are pleased to have worked with our banking partner to extend the Receivables Sale Program until October of 2029. The facility size remains unchanged, further ensuring the Company's liquidity strength, and we believe that this continued partnership demonstrates the strength of our accounts receivable portfolio and processes," said Jonathan Leon, EVP and Chief Financial Officer of Accendra Health, Inc.

Safe Harbor

This release is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the SEC's Fair Disclosure Regulation. This release contains certain "forward looking" statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of